Improper testing procedures and mishandling of samples can also produce inaccurate results." For instance, a drug test cannot distinguish between prescribed Tylenol with codeine and illicit opiates. In addition, without medical review and confirmation testing on initial positive results, 20 urine screens also cannot distinguish between the illicit use of street drugs and the legitimate use of certain prescription and over-the-counter drugs. Drug tests cannot measure frequency of use, nor do they indicate the severity of impairment or whether an individual has a substance use disorder that requires treatment. "Urine drug tests, which are the least expensive and most frequently used form of drug test, can generally detect marijuana use within the past week cocaine, heroin and other 'hard' drugs used within the past two days and alcohol use within the past several hours (though alcohol is not often included in drug screens). What Urine Drug Testing Can and Cannot Measure In the general US workforce, positivity increased 1.8% (5.5% in 2020 versus 5.6% in 2021) and was 12% higher than in 2017 (5.0% in 2017 versus 5.6% in 2021) and up each of the last 5 years."ĥ. "Overall positivity in the federally mandated, safety-sensitive workforce based on nearly 2.7 million urine drug tests stayed even year over year (2.2% in 20) and was 4.8% higher than 2017 (2.1% in 2017 versus 2.2% in 2021). Over 5 years, positivity for marijuana in the general US workforce increased 50% (2.6% in 2017 versus 3.9% in 2021). "Positivity rates for marijuana in the general US workforce based on more than 6 million urine tests continued an upward climb, increasing 8.3% (3.6% in 2020 versus 3.9% in 2021), the highest positivity rate ever reported in the DTI. Positivity Rate for Marijuana Use Among US Workers Subjected to Drug Testing "Employment Screening Benchmark Report, 2019 Edition," HireRight, Inc., 2019.Ĥ. The percentage of companies with a policy to test all candidates dropped by 12% since our 2018 survey."Ĭompanies That Subject Workers to Tests for Alcohol or Other Drugs:Ĭandidates for safety/ security concerned roles: 10%Ĭandidates for non-exempt/ hourly positions: 10%Ĭandidates for director and manager positions: 7%Ĭandidates for positions dealing with finances: 6%Ĭandidates for C-suite/ executive positions: 5% "While almost two-thirds of respondents drug test all candidates, the remainder of companies drug test only candidates for specific positions. Prevalence of Employment-Related Testing for Use of Alcohol or Other Drugs of Energy Office of Security Policy, by the Center for Human Reliability Studies (Oak Ridge, TN: Oak Ridge Institute for Science and Education, May 2007), p. "Drug Retention Times," Prepared for US Dept. For amphetamines, no metabolites are identified because these substances normally pass through the body essentially unchanged in chemical structure." Marijuana possesses the greatest total number of detectable metabolites at 31 but fewer major components. Identifying these compounds is the focus of workplace drug testing analysis. "A drug’s metabolite is the compound produced when the body processes a particular drug. Drug Testing Index and Industry Insights: 2022 Annual Report and Industry Insights. Table: Drug Positivity Rates Of US Employees Subjected to Urine Drug Tests, by Worker Category.Positivity Rates of Workers in the US Subjected to Drug Use Testing, by CategoryĪccording to Quest Analytics, the positivity rates in 2021 of workers in the US who were subjected to drug use testing in the context of employment are:įederally Mandated, Safety-Sensitive Workforce: 2.2% ![]() Table: Recommended Cut-Offs for Substances and Metabolites in Hair to Identify Drug Use.Table: Recommended Cut-Offs, Metabolites, and Cross-Reactors in Urine Drug Tests.At first blush, we see little to change our view of LabCorp’s narrow economic moat, as we think the firm’s significant cost advantage in its diagnostics business was compelling enough to warrant the moat even before its acquisition of Covance. This news comes on the heels of the firm’s strategic review in 2021 that culminated in the decision six months ago to hold on to its drug development segment. Perhaps the bigger news was the firm’s announcement that it would spin off its clinical drug development division (legacy Covance) in 2023. Nonetheless, these results do not deviate significantly from our estimates for 2022, and we’re maintaining our assumptions. With quarterly diagnostic revenue down 4.7%, LabCorp’s performance in this segment was a hair worse than what was seen at rival Quest Diagnostics. With these effects reverberating through the top and bottom lines, the firm remains on track to reach our full-year projections, and we’re leaving our fair value estimate unchanged. LabCorp’s second-quarter results generally met our expectations for continued softening in COVID-19 PCR tests.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |